Nick Fullenkamp

Nick Fullenkamp has over 18 years of experience in corporate development and business roles in the biotechnology and pharmaceutical industries. Nick is currently Vice President of Corporate Development at Vaccitech, a position they have held since December 2021. Prior to this, Nick served as Chief Business Officer at Avidea Technologies, a biotechnology company focused on precision immunotherapies, which was acquired by Vaccitech in December 2021. Before that, they worked as a Corporate Development Professional at Life Sciences Consulting from October 2019 to December 2021. From December 2018 to September 2019, Nick was Vice President of Corporate Development at Intrexon Corporation. Nick also held various roles at Emergent BioSolutions, including Senior Director and Director of Corporate Development, as well as Senior Manager of Corporate Development and Manager of Government Accounts. Earlier in their career, Nick worked as a Clinical Research Associate at Intercell USA and IOMAI Corporation, and as a Toxicologist at Gene Logic. Overall, Nick has a strong background in corporate development strategy and deal execution in the life sciences industry.

Nick Fullenkamp completed their Bachelor of Science degree in Integrated Science and Technology at James Madison University from 1998 to 2002. Nick later pursued a Master of Business Administration degree in Finance at the University of Maryland - Robert H. Smith School of Business from 2008 to 2011.